The Conversation (0)
Veritas Pharma (CSE:VRT,OTC:VRTHF,FWB:2VP) has received a quarterly research report from Cannevert Therapeutics Limited (CTL), lead researcher for Veritas, outlining both general and scientific progress since their last update.
Veritas Pharma (CSE:VRT,OTC:VRTHF,FWB:2VP) has received a quarterly research report from Cannevert Therapeutics Limited (CTL), lead researcher for Veritas, outlining both general and scientific progress since their last update.
As quoted in the press release:
Overall, CTL is a fully functional research company able to efficiently determine the amounts of cannabinoids present in different cultivars with precision and accuracy. This is to confirm that the materials received from cannabis suppliers have the purported characteristics, especially the cannabinoids of interest. In their initial animal studies, CTL has identified a number of cultivars with analgesic actions. They are now performing secondary screening, in particular, the collection of dose-response data for all pharmacological types of actions. The company continues to source more strains across Canada with potential therapeutic characteristics of interest. From a finance perspective, it has been fiscally responsible while ensuring that a six-month operational window is in place at all times. Its funding has been improved by obtaining grants to help reduce research costs for personnel salaries. It has now accumulated a total of 16 committed personnel, comprising faculty, research associates, postdoctoral fellows, graduate students and co-op students. For the remainder of the year, Cannevert aims to acquire more skilled workers, identify further appropriate cultivars or mixtures of cultivars with therapeutic potential, and initiate planning for future clinical trials.
